Taste Properties of HIV Inhibitor

NCT02608918 — Phase 1, Completed, 8 participants, ViiV Healthcare

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

An Open-Label Taste Assessment of BMS-955176 in Healthy Subjects

Registry	NCT02608918
Status	Completed
Phase	Phase 1
Study type	Interventional; na, single group, masking: none, other
Enrollment	8 (Actual)
Sponsor	ViiV Healthcare (Industry); collaborators: Senopsys, LLC
Conditions	HIV Infections
Interventions	BMS-955176 (Drug)
Dates	start 2016-01-05, primary completion 2016-05-24, completion 2016-05-24, first posted 2015-11-20, last updated 2018-04-17
Locations	1 site in United States

-Summary

The purpose of the study is to assess the taste properties of HIV inhibitor

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
BMS-955176	Experimental	Drug: BMS-955176	BMS-955176 specified dose on specified days

BMS-955176 (Drug), also known as HIV Maturation Inhibitor

+Outcome measures

Primary outcomes

Taste properties of HIV Inhibitor will be measured using the Flavor Profile of the Flavor Leadership Criteria [Up to 2 years]

+Eligibility

Sex: All, ages: 25 Years to 80 Years, accepts healthy volunteers

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

* Men and women of non-childbearing potential professional sensory panelists
* Aged between 25 and 80 years

Exclusion Criteria:

* History of relevant drug or food allergies, cardiovascular or Central nervous system (CNS) disease, clinically significant pathology, history of mental illness
* Positive HIV test

+Locations (1)

Facility	City	Country	Status
GSK Investigational Site	Woburn, Massachusetts	United States

+Investigators

Viiv Clinical Trials, Study director, ViiV Healthcare

My Notes

Public

To Read Reading Read